Used in research and development of targeted therapies for B-cell malignancies, particularly certain types of non-Hodgkin lymphoma and chronic lymphocytic leukemia. Binds specifically to FcRL5 (also known as IRTA2), a receptor expressed predominantly on mature B-cells and aberrantly on malignant B-cells, enabling selective targeting of diseased cells. Serves as a critical tool in antibody-drug conjugate (ADC) platforms, where it delivers cytotoxic agents directly to cancer cells while sparing healthy tissues. Also utilized in flow cytometry and immunohistochemistry for detection and isolation of FcRL5-positive B-cell populations. Supports studies on B-cell signaling and immune regulation due to its role in modulating receptor activity.